J. Friedberg

J. Friedberg, O. Hyrien, L. Constine, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.

Zheng Zhou, A. Rademaker, L. Gordon, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

J. Friedberg, J. Leonard, B. Cheson, 2015 .

Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of CancerA Multi-institutional Cohort StudyInterinstitutional Variation in Cancer Management Decisions

H. Uno, J. Friedberg, D. Schrag, 2014 .

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

I. Lossos, J. Friedberg, A. Agarwal, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Lymphoma Associated With Breast Implants: Two Case-reports and a Review of the Literature

J. Friedberg, G. Pinkus, A. Weng, 2002, Leukemia & lymphoma.

The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

J. Friedberg, R. Fisher, P. Dent, 2013, British journal of haematology.

Overcoming Rituximab Resistance: The US Clinical Experience With Bendamustine

J. Friedberg, 2007 .

Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.

J. Friedberg, 2005, Hematology. American Society of Hematology. Education Program.

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

A. LaCasce, J. Connors, J. Friedberg, 2020, Hematological oncology.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Derick R. Peterson, J. Friedberg, R. Fisher, 2016, Leukemia & lymphoma.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

A. LaCasce, J. Friedberg, R. Fisher, 2009, Clinical lymphoma & myeloma.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Sonali M. Smith, A. LaCasce, J. Friedberg, 2019, Blood.

Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma

J. Friedberg, R. Fisher, 2004, Expert review of anticancer therapy.

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.

W. Wilson, A. Zelenetz, J. Friedberg, 2020, Blood.

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

R. Advani, A. Zelenetz, J. Friedberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

A. Zelenetz, J. Friedberg, L. Constine, 2016, Blood.

Brentuximab vedotin for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma

J. Friedberg, P. Reagan, 2015 .

Hodgkin lymphoma: answers take time!

J. Friedberg, 2011, Blood.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Sonali M. Smith, J. Friedberg, L. Rimsza, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Evaluation

J. Friedberg, J. Armitage, 2020, Hodgkin Lymphoma.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis

R. Advani, R. Gascoyne, Sonali M. Smith, 2018, Cancer.

Gemcitabine and Other New Cytotoxic Drugs: Will Any Find Their Way Into Primary Therapy?

J. Friedberg, D. Dougherty, 2010, Current hematologic malignancy reports.

Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma.

J. Friedberg, L. Constine, J. Liesveld, 2009, International journal of radiation oncology, biology, physics.

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease

J. Friedberg, D. Neuberg, D. Fisher, 2003, Cancer.

Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma

J. Friedberg, P. Barr, Sudy Jahangiri, 2014, Expert opinion on emerging drugs.

Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.

J. Friedberg, R. Fisher, L. Constine, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood advances.

A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma

W. Wilson, S. Steinberg, J. Friedberg, 2019 .

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Sonali M. Smith, J. Friedberg, R. Fisher, 2018, The Lancet. Haematology.

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

G. Salles, J. Friedberg, C. Flowers, 2017, Blood.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

J. Vose, J. Friedberg, B. Cheson, 2014, Clinical immunology.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Armitage, J. Vose, 2011, Blood.

PET positive, PET negative, or PET peeve?

J. Friedberg, 2010, Blood.

752 2 8 J a N U a R Y 2 0 1 0 I V O L U M E 1 1 5 , N U M B E R 4 Blood

Sh, J. Friedberg, Rodrigues, 2022 .

Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept

A. D. Van den Abbeele, J. Friedberg, D. Neuberg, 2008, Leukemia & lymphoma.

Classical Hodgkin lymphoma

J. Friedberg, P. Brice, E. Kerviler, 2021, The Lancet.

Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial

Sonali M. Smith, J. Friedberg, L. Swinnen, 2017, Leukemia & lymphoma.

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

I. Lossos, J. Friedberg, J. Leonard, 2022, Blood advances.

Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs

J. Friedberg, C. Flowers, K. Yeager, 2019, Leukemia & lymphoma.

Burkitt lymphoma- a rare but challenging lymphoma.

J. Friedberg, C. Casulo, 2018, Best practice & research. Clinical haematology.

Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.

J. Friedberg, Julia Schaefer-Cutillo, 2008, Seminars in hematology.

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

J. Friedberg, R. Fisher, O. Hyrien, 2010, International journal of radiation oncology, biology, physics.

Developing New Monoclonal Antibodies for Aggressive Lymphoma

J. Friedberg, 2004, Clinical Cancer Research.

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

A. Zelenetz, J. Friedberg, C. Flowers, 2017, Leukemia & lymphoma.

Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma.

J. Friedberg, Thomas D. Rodgers, 2020, Hematology/oncology clinics of North America.

Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma

J. Friedberg, L. Calvi, J. Kelly, 2015, Leukemia & lymphoma.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

J. Friedberg, J. Winter, L. Rimsza, 2013, The New England journal of medicine.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Sonali M. Smith, J. Friedberg, J. Leonard, 2015, Blood.

Recommendations for Clinical Trial Development in Follicular Lymphoma

L. Gordon, J. Friedberg, J. Leonard, 2017, Journal of the National Cancer Institute.

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

J. Friedberg, R. Fisher, R. J. Kelleher, 2009, Blood.

A case–control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults

J. Friedberg, S. Fisher, L. Calvi, 2010, Cancer Causes & Control.

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2016 .

Chemotherapy free treatment of indolent lymphoma

J. Friedberg, C. Casulo, 2017, Hematological oncology.

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Leukemia & lymphoma.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, A. Zelenetz, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma

J. Friedberg, A. Freedman, 2006, Current treatment options in oncology.

Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2022, Haematologica.

Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors.

J. Friedberg, S. Ramsey, J. Peppercorn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison

A. D. Van den Abbeele, J. Friedberg, A. Fischman, 2004, Leukemia & lymphoma.

inducible gene expression, without significant toxicity - β / α interferon- rituximab in patients with non-Hodgkin lymphoma: increased Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and

J. Friedberg, R. Coffman, A. Freedman, 2013 .

A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.

J. Friedberg, L. Constine, J. Liesveld, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Derick R. Peterson, J. Friedberg, R. Fisher, 2009, British journal of haematology.

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

L. Gordon, M. Czuczman, J. Friedberg, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

J. Friedberg, R. Coffman, A. Freedman, 2005, Blood.

Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma

J. Friedberg, D. Neuberg, T. Spitzer, 2003, Bone Marrow Transplantation.

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.

A. Alizadeh, Sonali M. Smith, J. Friedberg, 2021, Journal of geriatric oncology.

Recent advances in the development of Aurora kinases inhibitors in hematological malignancies

J. Friedberg, P. Barr, I. Choudary, 2015, Therapeutic advances in hematology.

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

I. Lossos, J. Friedberg, D. Mahadevan, 2011 .

Symptomatic intracardiac diffuse large B‐cell lymphoma

J. Friedberg, J. Bisognano, S. Bernstein, 2009, American journal of hematology.

High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era

J. Friedberg, L. Constine, J. Liesveld, 2012, Leukemia & lymphoma.

Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies.

J. Friedberg, Rohit Sud, 2009, Oncology.

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

J. Friedberg, Rohit Sud, 2008, Haematologica.

Monoclonal antibodies in lymphoma: the first decade.

J. Friedberg, B. Link, 2008, Seminars in hematology.

Rituximab for early-stage diffuse large-B-cell lymphoma.

J. Friedberg, 2006, The Lancet. Oncology.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

D. Scott, Sonali M. Smith, J. Friedberg, 2019, Blood.

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2013, British journal of haematology.

CLL microenvironment: macro important.

J. Friedberg, 2011, Blood.

microenvironment: macro important

J. Friedberg, Jonathan W. Friedberg, 2011 .

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma

J. Friedberg, J. Leonard, M. Leblanc, 2017, Journal of the National Cancer Institute.

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

R. Advani, R. Gascoyne, L. Gordon, 2016 .

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

J. Friedberg, P. Reagan, J. Kelly, 2016, Clinical lymphoma, myeloma & leukemia.

Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

J. Friedberg, J. Goldschmidt, R. Sims, 2020 .

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

T. Larson, J. Friedberg, R. Bordoni, 2019, Blood.

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

J. Friedberg, P. Flynn, B. Holkova, 2018 .

Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma.

J. Friedberg, 2006, Haematologica.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

R. Advani, J. Connors, J. Friedberg, 2022, The New England journal of medicine.

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

J. Gribben, J. Friedberg, D. Neuberg, 2004, Leukemia research.

Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience.

J. Friedberg, P. Rothberg, A. Andersen, 2006, Leukemia research.

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP

D. Scott, J. Friedberg, T. Habermann, 2019, Hematological Oncology.

End of rituximab maintenance for low-tumor burden follicular lymphoma.

J. Friedberg, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

J. Cerhan, J. Friedberg, C. Flowers, 2011 .

Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

J. Friedberg, B. Cheson, L. Tremmel, 2010, Clinical lymphoma, myeloma & leukemia.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Sonali M. Smith, J. Friedberg, J. Winter, 2019, Leukemia & lymphoma.

Management of marginal zone lymphoma.

J. Friedberg, Robin M. Reid, 2013, Oncology.

The emerging role of bendamustine in follicular lymphoma

J. Friedberg, 2009, Leukemia & lymphoma.

Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.

J. Friedberg, R. Fisher, Julia Schaefer-Cutillo, 2007, Oncology.

Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).

J. Friedberg, J. Winter, R. Fisher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

L. Staudt, W. Wilson, S. Steinberg, 2014 .

Reply to M.C. Chamberlain

J. Friedberg, R. Fisher, T. Miller, 2009 .

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

R. Advani, J. Friedberg, S. Horwitz, 2005 .

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

J. Friedberg, P. Reagan, C. Zent, 2019, Clinical lymphoma, myeloma & leukemia.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

J. Friedberg, I. Flinn, K. Rai, 2015, Blood.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Intra‐arterial methylprednisolone for the management of steroid‐refractory acute gastrointestinal and hepatic graft versus host disease

J. Friedberg, G. Holland, J. Liesveld, 2011, American journal of hematology.

Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?

J. Friedberg, H. Schoder, D. Stephens, 2020, The Journal of Nuclear Medicine.

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Sonali M. Smith, J. Friedberg, J. Leonard, 2017 .

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL

R. Gascoyne, D. Scott, J. Friedberg, 2017 .

An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.

J. Friedberg, M. Leblanc, K. Kelly, 2020 .

Novel agents in mantle cell lymphoma.

J. Friedberg, P. Barr, M. Noel, 2012, Best practice & research. Clinical haematology.

Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012, Molecular Cancer Therapeutics.

Preclinical Development Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Car fi lzomib in GC-and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012 .

Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma.

J. Friedberg, L. Constine, J. Liesveld, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Sonali M. Smith, A. LaCasce, J. Friedberg, 2018, Blood.

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

L. Gordon, A. LaCasce, A. Vanderplas, 2010 .

Late Relapses After High‐dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B‐cell Lymphoma in the Rituximab Era

J. Friedberg, L. Constine, J. Liesveld, 2017, Clinical lymphoma, myeloma & leukemia.

Stem cell transplantation in non-Hodgkin lymphomas

J. Friedberg, S. Hashmi, 2013 .

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

J. Friedberg, A. Ng, B. Silver, 2002, Blood.

Reply to H.J.A. Adams et al and E.A. Hawkes et al.

J. Friedberg, O. Press, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma

J. Friedberg, R. Fisher, A. Walker, 2008, Cancer investigation.

Preclinical Development Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011 .

Radioimmunotherapy for Non-Hodgkin’s Lymphoma

J. Friedberg, 2004, Clinical Cancer Research.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma

J. Friedberg, P. Reagan, C. Zent, 2020, Leukemia & lymphoma.

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.

J. Gribben, J. Friedberg, B. Cheson, 2010, Clinical lymphoma, myeloma & leukemia.

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

J. Cerhan, A. Zelenetz, J. Friedberg, 2019, British journal of haematology.

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

J. Friedberg, P. Reagan, 2017, Oncology.

Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma

A. LaCasce, J. Friedberg, J. Leonard, 2017, British journal of haematology.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

J. Friedberg, B. Holkova, J. Goldschmidt, 2015, Blood.

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2015 .

Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

W. Wilson, J. Friedberg, J. Leonard, 2020, Leukemia & lymphoma.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

W. Wilson, S. Steinberg, A. LaCasce, 2018, The Lancet. Haematology.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

R. Advani, A. Nademanee, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adult Burkitt Lymphoma and Leukemia

J. Friedberg, G. Ott, E. Hsi, 2014 .

Bendamustine in chronic lymphocytic leukemia: the future is combination therapy

J. Friedberg, 2009, Leukemia & lymphoma.

The Role of Bortezomib in the Treatment of Lymphoma

J. Friedberg, R. Fisher, P. Barr, 2007, Cancer investigation.

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

J. Vose, J. Friedberg, B. Cheson, 2013, Leukemia & lymphoma.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

J. Friedberg, B. Cheson, S. O'brien, 2016, Blood.

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

D. Weisenburger, J. Cerhan, O. Nanni, 2014, Journal of the National Cancer Institute. Monographs.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

J. Friedberg, B. Cheson, Michael E. Williams, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment

J. Friedberg, M. Cragg, Peter W. M. Johnson, 2018, Mechanical Engineering Series.

Treating Burkitt Lymphoma in Adults

J. Friedberg, C. Casulo, 2015, Current Hematologic Malignancy Reports.

Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells

J. Friedberg, D. Porter, P. Rothberg, 2015, British journal of haematology.

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo

J. Friedberg, S. Grant, M. Rahmani, 2014, Clinical Cancer Research.

Relapsed/refractory diffuse large B-cell lymphoma.

J. Friedberg, 2011, Hematology. American Society of Hematology. Education Program.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Ronald Levy, John P Leonard, Patrick B Johnston, 2010, Blood.

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma

J. Gribben, J. Friedberg, D. Neuberg, 2002, British journal of haematology.

Diffuse large B-cell lymphoma.

J. Friedberg, R. Fisher, 2008, Hematology/oncology clinics of North America.

Chapter 17 – Large-Cell Lymphoma

J. Friedberg, 2006 .

Burkitt lymphoma in adults.

J. Friedberg, A. Perkins, Jonathan W Friedberg, 2008, Hematology. American Society of Hematology. Education Program.

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.

J. Friedberg, P. Flynn, A. Forero-Torres, 2017, Blood.

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

R. Advani, R. Gascoyne, L. Gordon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Hodgkin lymphoma: a 50-year perspective.

J. Friedberg, T. Lister, V. Devita, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

J. Friedberg, R. Fisher, P. Dent, 2010, Leukemia research.

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

Sonali M. Smith, J. Friedberg, J. Leonard, 2017, British journal of haematology.

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Blood.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma

J. Friedberg, P. Reagan, Patrick M Reagan, 2015, Current Treatment Options in Oncology.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

J. Connors, J. Friedberg, J. Leonard, 2017, Journal of the National Cancer Institute.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.

J. Gribben, A. LaCasce, J. Friedberg, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transformed follicular non-Hodgkin lymphoma.

J. Friedberg, W. R. Burack, J. Wilmot, 2015, Blood.

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

L. Gordon, A. LaCasce, A. Vanderplas, 2013, Cancer.

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

J. Friedberg, D. Neuberg, A. Freedman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

with or without chemotherapy: long-term risks and risk factors Second malignancy after Hodgkin disease treated with radiation therapy

J. Friedberg, A. Ng, B. Silver, 2013 .

Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.

J. Gribben, J. Friedberg, D. Neuberg, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chapter 30 – Hodgkin's Lymphoma: Diagnosis and Treatment

J. Friedberg, 2006 .

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

D. Scott, J. Friedberg, J. Leonard, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

J. Friedberg, R. Fisher, T. Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

J. Friedberg, S. Ansell, D. Porter, 2020, Journal for ImmunoTherapy of Cancer.

Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia.

J. Friedberg, J. Bennett, D. Kilari, 2013, Leukemia research reports.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Clinical Cancer Research.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab in indolent lymphomas.

J. Friedberg, Tarek Sousou, Jonathan Friedberg, 2010, Seminars in hematology.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

R. Advani, L. Gordon, J. Connors, 2019, Clinical Cancer Research.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Sonali M. Smith, J. Friedberg, L. Rimsza, 2018, American journal of hematology.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, Leukemia & lymphoma.

ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma.

R. Advani, J. Friedberg, C. Flowers, 2010, Current problems in cancer.

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

J. Friedberg, A. Ng, B. Silver, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

J. Friedberg, R. Fisher, D. Neuberg, 2009, British journal of haematology.

Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma

J. Gribben, J. Friedberg, D. Neuberg, 2004, Leukemia & lymphoma.

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.

J. Gribben, J. Friedberg, A. Freedman, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

J. Friedberg, J. Liesveld, C. Abboud, 2006, Leukemia research.

Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation

J. Friedberg, O. Hyrien, L. Constine, 2011 .

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

W. Wilson, S. Steinberg, P. Bierman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

J. Friedberg, R. Fisher, P. Dent, 2009, Cancer biology & therapy.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

L. Gordon, J. Friedberg, R. Coffman, 2018, Cancer discovery.

How I treat double-hit lymphoma.

J. Friedberg, 2017, Blood.

T‐Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

J. Friedberg, J. Leonard, S. Horwitz, 2017, Journal of the National Cancer Institute.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era

J. Cerhan, J. Friedberg, C. Flowers, 2016, British journal of haematology.

Diffuse large B-cell NHL.

J. Friedberg, R. Fisher, 2006, Cancer treatment and research.

Unmet needs in the first-line treatment of follicular lymphoma

J. Friedberg, C. Flowers, C. Casulo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Transformation of marginal zone lymphoma (and association with other lymphomas).

J. Friedberg, C. Casulo, 2017, Best practice & research. Clinical haematology.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

J. Friedberg, I. Flinn, Y. Oki, 2014, The Lancet. Oncology.

Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

J. Cerhan, J. Friedberg, C. Flowers, 2015, Leukemia & lymphoma.

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Sonali M. Smith, J. Friedberg, M. Leblanc, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

diffuse large B-cell lymphoma treated in the rituximab era An enhanced International Prognostic Index (NCCN-IPI) for patients with

R. Gascoyne, L. Sehn, Zheng Zhou, 2014 .

New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice Friedberg Dlbcl Gene Expression Profiling 2

J. Friedberg, Research, 2022 .

CCR New Strategies New Strategies in Diffuse Large B-cell Lymphoma : Translating Findings from Gene Expression Analyses into Clinical Practice

J. Friedberg, 2011 .

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

J. Vose, S. Montoto, Sonali M. Smith, 2019, JAMA oncology.

Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.

J. Friedberg, 2015, Hematology. American Society of Hematology. Education Program.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States

J. Cerhan, A. Zelenetz, J. Friedberg, 2015, British journal of haematology.

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

J. Cerhan, J. Friedberg, C. Flowers, 2014, Cancer.

Rituximab maintenance in follicular lymphoma: PRIMA

J. Friedberg, 2011, The Lancet.

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

J. Cerhan, A. Zelenetz, J. Friedberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

W. Wilson, L. Sehn, Sonali M. Smith, 2016, Journal of the National Cancer Institute.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

S. Groshen, J. Friedberg, K. Venkatakrishnan, 2018, Clinical Cancer Research.

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

I. Lossos, J. Friedberg, P. Zinzani, 2022, Blood advances.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2013 .

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011, Molecular Cancer Therapeutics.

The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma.

J. Friedberg, D. Neuberg, A. Freedman, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose therapy and stem cell transplantation in follicular lymphoma

J. Friedberg, A. Freedman, 1999, Annals of Hematology.

High-dose therapy for follicular lymphoma.

J. Friedberg, A. Freedman, J. Gribben, 2000, Oncology.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Sonali M. Smith, J. Friedberg, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Introduction to Genomics in Hematologic Malignancy.

J. Friedberg, B. Ebert, 2017, Journal of Clinical Oncology.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

PET scans in the staging of lymphoma: current status.

J. Friedberg, V. Chengazi, 2003, The oncologist.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

J. Friedberg, R. Fisher, J. Liesveld, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular lymphoma in the United States: first report of the national LymphoCare study.

J. Cerhan, J. Vose, A. Zelenetz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seeking wisdom from the Seer

J. Friedberg, P. Mclaughlin, 2009, Leukemia & lymphoma.

Treatment of follicular non-Hodgkin's lymphoma: the old and the new.

J. Friedberg, Jonathan W Friedberg, 2008, Seminars in hematology.

Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapuetic regimens : Results from the international Burkitt lymphoma collaborative group

A. LaCasce, J. Friedberg, R. Fisher, 2005 .

R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433

A. Nademanee, M. Kaminski, J. Friedberg, 2014, British journal of haematology.

Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion.

J. Friedberg, I. Sanz, Chungwen Wei, 2012, Clinical immunology.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A. LaCasce, J. Friedberg, I. Flinn, 2016, European journal of cancer.

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Friedberg, J. Liesveld, B. Hill, 2020, Blood.

Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.

J. Friedberg, B. Cheson, B. Kahl, 2010, Clinical advances in hematology & oncology : H&O.

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma

J. Friedberg, M. Strawderman, D. Topham, 2020, Leukemia.

Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.

J. Friedberg, I. Flinn, S. O'brien, 2012 .

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

L. Staudt, W. Wilson, A. Zelenetz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rare B Cell Lymphoproliferative Disorders

J. Friedberg, P. Barr, 2012 .

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents

J. Friedberg, G. Holland, J. Liesveld, 2011 .

Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline

J. Friedberg, R. Deshaies, H. Land, 2015, Oncotarget.

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

R. Greil, J. Burke, G. Salles, 2021, The New England journal of medicine.

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

High risk of eosinophilia in women treated with clozapine.

J. Friedberg, M. Tohen, M. Banov, 1993, The Journal of clinical psychiatry.

Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

Philip R. Cohen, J. Friedberg, B. Cheson, 2005 .

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective

J. Friedberg, J. Liesveld, M. Becker, 2016, Cancer medicine.

EXABS-196-ABCL Has R-CHOP Really Been Replaced as Initial Therapy of Diffuse Large B-cell Lymphoma (DLBCL)?

J. Friedberg, 2022, Clinical lymphoma, myeloma & leukemia.

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

G. Salles, L. Sehn, J. Friedberg, 2019, Journal of Clinical Oncology.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Friedberg, L. Rimsza, 2014, Blood.

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

J. Friedberg, R. Fisher, G. Lyman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, British journal of haematology.

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

J. Friedberg, J. Lancet, J. Liesveld, 2004, Seminars in oncology.

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Scott E. Smith, J. Friedberg, A. Younes, 2014, Leukemia & lymphoma.

Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015

B. Nadel, K. Tarte, R. Gascoyne, 2017, Hematological oncology.

Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Cancer.

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Leukemia & lymphoma.

Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database

L. Gordon, A. LaCasce, A. Vanderplas, 2013, Leukemia & lymphoma.

Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2014, Cancer.

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Sonali M. Smith, M. Kaminski, J. Friedberg, 2016 .

Wormy mothers, healthy babies: case closed or conundrum?

J. Friedberg, P. James, 2011 .

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.

J. Friedberg, 2015, Chinese clinical oncology.

How I Treat How I treat double-hit lymphoma

J. Friedberg, J. Wilmot, 2017 .

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation

J. Friedberg, K. Loh, P. Reagan, 2019, Leukemia & lymphoma.

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

J. Cerhan, A. Zelenetz, J. Friedberg, 2016, American journal of hematology.

Double-hit diffuse large B-cell lymphoma.

J. Friedberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study)

J. Friedberg, J. Zaucha, M. Izquierdo, 2021, British journal of haematology.

Toward a Cure for Follicular Lymphoma.

J. Friedberg, 2020, Hematology/oncology clinics of North America.

General Biomarker Recommendations for Lymphoma.

L. Staudt, K. Fu, R. Gascoyne, 2016, Journal of the National Cancer Institute.

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

A. Zelenetz, J. Friedberg, C. Flowers, 2013 .

Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study

A. Zelenetz, J. Friedberg, C. Flowers, 2013 .

Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

A. LaCasce, A. Zelenetz, G. Abel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Getting to the heart of the problem in treating diffuse large B-cell lymphoma

J. Friedberg, P. Barr, 2011, Leukemia & lymphoma.

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, Blood.

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

I. Lossos, J. Friedberg, P. Zinzani, 2020 .

Efficacy of lenalidomide in high‐risk diffuse large B‐cell lymphoma

J. Friedberg, P. Reagan, R. Burack, 2019, British journal of haematology.

Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

I. Lossos, J. Cerhan, J. Friedberg, 2022, Blood advances.

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2015, Cancer.

Treatment of early-stage follicular lymphoma: do as I say, not as I do

J. Friedberg, C. Casulo, 2013 .

Racial differences in presentation and management of follicular non‐Hodgkin lymphoma in the United States

J. Cerhan, J. Friedberg, C. Flowers, 2012, Cancer.

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma

J. Friedberg, M. Sikder, 2008, Current oncology reports.

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma

J. Friedberg, M. Sikder, 2008, Current hematologic malignancy reports.

Novel Agents for Hematologic Malignancies: An Era of Riches

J. Friedberg, 2007 .

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.

J. Friedberg, S. Bernstein, P. Barr, 2011, Leukemia research.

Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

J. Friedberg, B. Cheson, K. Rai, 2011, Clinical advances in hematology & oncology : H&O.

Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS).

J. Vose, A. Zelenetz, J. Friedberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

J. Friedberg, R. Fisher, P. Dent, 2010, Blood.

Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

R. Advani, R. Gascoyne, L. Gordon, 2015, British journal of haematology.

Complications Associated With Dose‐adjusted EPOCH‐rituximab Therapy for Non‐Hodgkin Lymphoma

J. Friedberg, K. Loh, P. Reagan, 2018, Clinical lymphoma, myeloma & leukemia.

Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Sonali M. Smith, J. Friedberg, J. Winter, 2016, British journal of haematology.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

Sonali M. Smith, J. Friedberg, J. Leonard, 2018, Haematologica.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

R. Advani, R. Gascoyne, L. Gordon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse.

J. Friedberg, L. Constine, J. Liesveld, 2016, International journal of radiation oncology, biology, physics.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

J. Friedberg, R. Fisher, T. Miller, 2015, Blood.

Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.

J. Friedberg, J. Nelson, A. Rodday, 2023, JAMA cardiology.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

I. Lossos, J. Vose, R. Gascoyne, 2017, Blood advances.

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

J. Friedberg, J. Leonard, B. Cheson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.

Jennifer Kelly, Joshua N Sampson, Wendy Cozen, 2014, Journal of the National Cancer Institute. Monographs.

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

L. Gordon, A. LaCasce, A. Vanderplas, 2010 .

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study

J. Cerhan, J. Friedberg, C. Flowers, 2013, Cancer.

Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.

J. Friedberg, J. Nelson, A. Rodday, 2021, Journal of geriatric oncology.

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

J. Friedberg, R. Fisher, R. Coffman, 2005 .

Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time?

J. Friedberg, S. Mohile, K. Loh, 2019, Journal of the National Cancer Institute.

OP-JNCI180265 757..759

J. Friedberg, S. Mohile, K. Loh, 2019 .

First‐line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)‐Medicare population‐based study

J. Friedberg, A. Rodday, P. Lindenauer, 2020, British journal of haematology.

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II.

R. Advani, J. Friedberg, C. Flowers, 2011, Journal of the American College of Radiology : JACR.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

M. Kaminski, M. Czuczman, J. Friedberg, 2011 .

Bak to death with chemotherapy.

J. Friedberg, 2008, Blood.

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

Weidong Lu, Dan Xi, Mark Levine, 2017, Journal of the National Cancer Institute. Monographs.

Clozapine-caused eosinophilic colitis.

J. Friedberg, F. Frankenburg, W. Johnson, 1995, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2019, Molecular Cancer Therapeutics.

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

J. Friedberg, K. Savage, A. Rodday, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma

J. Friedberg, A. Rodday, P. Lindenauer, 2021, JAMA network open.

RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R

W. Wilson, J. Friedberg, K. Dunleavy, 2017 .

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

J. Vose, A. LaCasce, J. Friedberg, 2008 .

Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma

A. D. Van den Abbeele, J. Friedberg, G. Demetri, 1999, Cancer.

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Vitamin D and Non-Hodgkin Lymphoma Risk in Adults: A Review

J. Friedberg, S. Fisher, L. Calvi, 2009, Cancer investigation.

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

J. Friedberg, P. Reagan, 2015, Future oncology.

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

J. Friedberg, R. Fisher, T. Miller, 2008 .

Salvage therapy in Hodgkin's lymphoma.

J. Friedberg, J. Mendler, 2009, The oncologist.

Arrhythmia Burden in Patients with Indolent Lymphoma

J. Friedberg, I. Goldenberg, S. McNitt, 2020, Blood.

Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics

J. Friedberg, 2004 .

Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study.

Hajime Uno, Deborah Schrag, Nathan Taback, 2014, Annals of internal medicine.

Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non‐Hodgkin lymphoma (NHL) multicenter outcomes database

Michelle E Kho, Joyce C Niland, Jane C Weeks, 2008, Cancer.

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

L. Gordon, M. Czuczman, J. Friedberg, 2005 .

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

J. Friedberg, J. Leonard, S. Gore, 2021, Blood.

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

R. Gascoyne, D. Scott, M. Czuczman, 2019, Blood.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

J. Friedberg, Kriti Thapa, P. Reagan, 2023, Clinical lymphoma, myeloma & leukemia.

Update on follicular lymphoma

J. Friedberg, 2023, Hematological oncology.

POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL

G. Salles, J. Friedberg, M. Trněný, 2019, Hematological Oncology.

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

J. Friedberg, J. Leonard, T. Witzig, 2019, Blood.

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.

R. Advani, J. Connors, J. Friedberg, 2022, Journal of Clinical Oncology.

Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.

I. Lossos, J. Cerhan, J. Friedberg, 2018 .

Autologous Transplantation (autoHCT) is Associated with Improved Overall Survival (OS) in Follicular Lymphoma (FL) Patients (Pts) Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis

Sonali M. Smith, J. Friedberg, K. Ahn, 2017 .

Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2011, Journal of Clinical Oncology.

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

J. Friedberg, P. Reagan, C. Zent, 2023, Blood advances.

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

J. Friedberg, I. Flinn, K. Rai, 2013 .

Immunotherapy for Hematologic Malignancies.

J. Friedberg, C. Craddock, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib.

J. Friedberg, R. Fisher, S. Grant, 2012 .

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort

I. Lossos, R. Advani, J. Vose, 2015, American journal of hematology.

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

R. Advani, R. Gascoyne, L. Gordon, 2011 .

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Scott E. Smith, L. Staudt, W. Wilson, 2016 .

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

J. Friedberg, R. Fisher, T. Miller, 2010 .

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

L. Gordon, A. LaCasce, A. Vanderplas, 2011 .

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Sonali M. Smith, J. Friedberg, J. Leonard, 2020 .

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

T. Larson, J. Friedberg, J. Goldschmidt, 2020 .

The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

J. Friedberg, K. Kelly, L. Constine, 2021, Blood.

Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).

Joshua T. Cohen, J. Raemaekers, J. Friedberg, 2020 .

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2017 .

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

J. Friedberg, J. Leonard, B. Cheson, 2020 .

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Sonali M. Smith, J. Friedberg, J. Leonard, 2023, Journal of Clinical Oncology.

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

W. Wilson, J. Friedberg, J. Leonard, 2023, Cancer medicine.

Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

J. Friedberg, B. Cheson, S. O'brien, 2014 .

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

J. Friedberg, B. Holkova, A. Forero-Torres, 2013 .

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, New England Journal of Medicine.

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood.

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Friedberg, J. Liesveld, B. Hill, 2019, Blood.

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Sonali M. Smith, M. Kaminski, J. Friedberg, 2023, Blood advances.

U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).

J. Friedberg, C. Flowers, R. Fisher, 2014 .

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relapsed/refractory diffuse large B-cell lymphoma.

J. Friedberg, 2011, Hematology. American Society of Hematology. Education Program.

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

J. Friedberg, A. Wiestner, P. Barr, 2013, Leukemia.

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

J. Armitage, J. Vose, J. Friedberg, 2009 .

Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era

I. Lossos, R. Advani, J. Vose, 2013 .

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

A. LaCasce, J. Friedberg, R. Fisher, 2009, Clinical lymphoma & myeloma.

Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.

F. Jardin, L. Sehn, J. Friedberg, 2023, Journal of Clinical Oncology.

J. Cerhan, A. Zelenetz, J. Friedberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination treatment approaches and novel therapies for lymphoma.

J. Friedberg, J. Leonard, A. Levine, 2007, Clinical advances in hematology & oncology : H&O.

Diffuse large B-cell lymphoma.

J. Friedberg, R. Fisher, 2008, Hematology/oncology clinics of North America.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

J. Friedberg, O. Hyrien, L. Constine, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transformation of marginal zone lymphoma (and association with other lymphomas).

J. Friedberg, C. Casulo, 2017, Best practice & research. Clinical haematology.

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

J. Friedberg, R. Fisher, D. Neuberg, 2007 .